This Article Full Text Full Text (PDF) CME: Take the course for this article: Goals and Objectives in the Management of Metastatic Breast Cancer eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chung, C. T. Articles by Carlson, R. W. Search for Related Content PubMed PubMed Citation Articles by Chung, C. T. Articles by Carlson, R. W.

Goals and Objectives in the Management of Metastatic Breast Cancer

^a Division of Oncology, Stanford University, Stanford, California, USA; ^b Division of Oncology, Stanford University, Palo Alto, California, USA

Correspondence: Robert W. Carlson, M.D., Division of Oncology, Stanford University, 1000 Welch Road #202, Palo Alto, California 94304, USA. Telephone: 650-725-6457; Fax: 650-725-8222; e-mail: rcarlson{at}stanford.edu

Patients with metastatic breast cancer consist of a heterogeneous group of patients whose prognoses and clinical courses can vary depending on host factors, such as comorbidity and age, and on tumor factors, such as hormone-receptor status, grade, and anatomical site of disease. Although the median survival time for patients with metastatic breast cancer is 2–4 years, subsets of patients with either indolent or limited metastatic disease may have prolonged survival times. Further, expectations of treatment, both in terms of efficacy and of toxicity, vary greatly based upon the specific treatment, patient characteristics, and tumor characteristics. Thus, the goals of treatment for patients with metastatic breast cancer are influenced by estimates of prognoses as well as a balance between physician and patient preferences regarding efficacy and toxicity considerations. Traditionally, objective measures of response and survival have been the targeted end points in clinical trial design and in physician selection of therapy for metastatic breast cancer. More recently, issues of quality of life have surfaced as important end points, especially from the perspective of the patient. The decision-making process in selecting the optimal treatment for patients with metastatic breast cancer is, therefore, a multidimensional process involving subjective as well as objective goals of treatment. Ultimately, the benefits of treatment must justify the risks and toxicities of the treatment, and the impact of treatment should be measured in relation to specified goals. Both physician and patient perspectives are important in establishing the objectives of treatment, and this process is optimally an interactive and ongoing process throughout the course of disease.

Key Words. Goals of treatment • Metastatic breast cancer

This article has been cited by other articles:

				X. Pivot, P. Koralewski, J. L. Hidalgo, A. Chan, A. Goncalves, G. Schwartsmann, S. Assadourian, and J. P. Lotz A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients Ann. Onc., September 1, 2008; 19(9): 1547 - 1552. [Abstract] [Full Text] [PDF]

				L. B. Michaud Treatment-experienced breast cancer Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S4 - S9. [Abstract] [Full Text] [PDF]

				N. P. S. Crawford, J. Alsarraj, L. Lukes, R. C. Walker, J. S. Officewala, H. H. Yang, M. P. Lee, K. Ozato, and K. W. Hunter Bromodomain 4 activation predicts breast cancer survival PNAS, April 29, 2008; 105(17): 6380 - 6385. [Abstract] [Full Text] [PDF]

				B. L. Andersen, K. M. Carpenter, H.-C. Yang, and C. L. Shapiro Sexual Well-Being Among Partnered Women With Breast Cancer Recurrence J. Clin. Oncol., July 20, 2007; 25(21): 3151 - 3157. [Abstract] [Full Text] [PDF]

				C. A. Huff, W. Matsui, B. D. Smith, and R. J. Jones The paradox of response and survival in cancer therapeutics Blood, January 15, 2006; 107(2): 431 - 434. [Abstract] [Full Text] [PDF]

				T. Friess, W. Scheuer, and M. Hasmann Combination Treatment with Erlotinib and Pertuzumab against Human Tumor Xenografts Is Superior to Monotherapy Clin. Cancer Res., July 15, 2005; 11(14): 5300 - 5309. [Abstract] [Full Text] [PDF]